Scientific Experts

Dr. Ulrich Elling

Dr. Ulrich Elling studied Biology in Regensburg (Germany) and graduated in Molecular Biology from the EMBL in Heidelberg (Germany). During his postdoctoral work with Prof. Dr. Josef Penninger in Vienna (Austria) Ulrich became expert in genome-wide forward genetic screens in mammalian systems. He is a recognized world expert in genome-wide modification strategies and genetic engineering of genomes. Since 2006 he has been working at the IMBA. In 2015 he started his own research group, where he established as master mind the mouse haploid cell knockout library, the largest stem cell library in the world.


Scientific Experts

Dr. Martin Denzel

Dr. Martin Denzel studied Human Biology in Marburg (Germany) and performed his PhD at the Sanford Burnam Institute in San Diego (USA). He became expert in forward genetics during his postdoctoral work at the Max-Planck-Institute for Biology of Ageing in Cologne, where he started his own research laboratory in the department of ‘Molecular Genetics of Ageing’ in 2014. Dr. Martin Denzel will support the continuous improvement of our genetic screening platform as well as advise on selected drug development projects.


Scientific Experts

Dr. Moritz Horn

Dr. Moritz Horn studied Biochemistry at the University of Tübingen (Germany) and completed his PhD in Genetics from the University of Cologne (Germany). Working as postdoctoral fellow in the group of Dr. Martin Denzel at the Max Planck Institute for Biology of Ageing in Cologne (Germany), He became expert in forward genetic screens using cellular systems and led successful industry collaborations.


Scientific Advisory Board

Dr. Rao Movva

Dr. Rao Movva brings 40 years of broad experience, from the biotech and large pharmaceutical industry. He worked at Biogen, the first European biotech company in its founding years in Geneva and later at Sandoz and Novartis, Basel as executive director. At Sandoz, he was instrumental in developing the recombinant therapeutic protein production methodologies for clinical development.

Dr. Movva had initiated and pioneered the chemical biology efforts that led to the discovery and the understanding of the biological targets of rapamycin, the TOR pathways, in collaboration with Drs. Joseph Heitman and Mike Hall at Biozentrum, Basel. This significant milestone lead to the elucidation of the central role, these pathways play in cell growth and development. They also lead to the advancement of many currently marketed drugs in transplantation, cancer, restenosis and to the development of longevity drugs in many Biotech companies.

Dr. Movva and his team have contributed to multiple programs at Novartis that uncovered the mechanism of action of natural compounds to advance them as leads for drug discovery.

Dr. Movva was recognized as a Novartis Distinguished Scientist in 2012 for his many significant contributions at the company. He is currently an independent advisor and mentor to Pharma and biotech companies.


Scientific Advisory Board

Prof. Dr. Steve P. Jackson

Prof. Dr. Steve P. Jackson is Professor at Cambridge University, Head of Cancer Research UK Laboratories and part-time CSO of Mission Therapeutics. He will be instrumental to our anti-cancer research projects and has in-depth experience in the use of haploid stem cell systems and genetic screening systems. He performed the first synthetic lethal screens for cancer which lead to the development of the first in-class PARP inhibitor Olaparib, which is approved for the treatment of ovarian cancer and which his company developed and then sold to Astra Zeneca. Prof. Jackson will advise us on genetic screenings and drug developments based on such screens, also providing access to international investors through his extensive network.


Scientific Advisory Board

Dr. Norbert Bischofsberger

Dr. Norbert Bischofsberger received a Ph.D. in organic chemistry from Zurich’s ETH and received an honorary doctorate in Natural Sciences (2016) from The University of Innsbruck and an honorary doctorate in Letters in Medicine (2017) from Baylor College of Medicine. He is the President & Chief Executive Officer of Kronos Biotech and he was the Executive Vice President, Research and Development and Chief Scientific Officer at Gilead Sciences. He was part of the core management team that grew Gilead from less than 50 employees with no revenues to 10,000 employees with $25B in revenue.


Scientific Advisory Board

Dr. Bert Klebl

Dr. Bert Klebl is a medicinal chemist and the director of the LEAD drug discovery center (LDC) in Dortmund, Germany, which supports groups from Max Plan Institutes and also other institutions in a wide range of drug development projects. The LDC has been instrumental in developing multiple novel small molecules from hits to lead drug candidates and has also close relationships to multiple large pharmaceutical companies to scout for new drug opportunities. He will advise us and provide key strategic input on drug development strategies and medicinal chemistry for newly identified drug targets and support us in the target deconvolution.